|Bid||0.0000 x 4000|
|Ask||0.0000 x 3100|
|Day's Range||3.8600 - 4.0200|
|52 Week Range||1.2900 - 5.0300|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
Positive results announced earlier this week from an early-stage study led to another day of big gains for this clinical-stage biotech.
The biotech stock is enjoying a second day of big gains after the company reported promising results for experimental drug ACH-5228.
Bill Mathews, founder and contributing editor to The Cheap Investor, selected Achillian Pharmaceuticals (ACHN) as a more speculative idea for 2019. The stock has risen 69%. Here's his latest update on this biotech firm.
Anyone researching Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) might want to consider the historical volatility of...
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
On a per-share basis, the New Haven, Connecticut-based company said it had a loss of 14 cents. The company's shares closed at $2.88. A year ago, they were trading at $3.67. _____ This story was generated ...
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.
Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.
Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.
Achillion Pharmaceuticals, Inc.'s (NASDAQ:ACHN) most recent earnings announcement in December 2018 suggested company earnings became less negative compared to the previous year's level - great news for investors Today IRead More...